What a medical advisory board is and is not

The phrase carries no official status

There is no license for a medical advisory board, no registry of them and no published definition a company has to meet before using the words.

A company can convene one, name it, decide what it does, decide what it is paid and decide what to publish about it. All of those are the company's choices.

That is not an accusation. Advisory boards do real work in medicine and in industry. It is a statement about what the phrase on its own tells a reader, which is very little.

The useful question is therefore never whether a company has one. It is what the board did, who is on it, and how you would know either.

It is not the thing that prescribes

The most common misreading is that a published board is the clinical authority behind your treatment. It is not the same role.

Federal law ties a prescription to a practitioner licensed by law to administer the drug. Federal telehealth guidance then requires that clinician to be licensed or legally permitted to practice in the state where the patient is located.

An advisory board member has no such requirement, because advising a company is not treating a patient. A board can consist entirely of people licensed nowhere near you, and often does.

So a named board answers a marketing question about credibility. The prescribing question is answered by a different person, in your state, whose name may not appear anywhere on the site.

What the advertising rules actually require

This is where enforceable standards do exist, and they are stricter than the phrase implies.

Federal trade rules define an endorsement broadly. It is any advertising, marketing or promotional message consumers are likely to believe reflects the opinions, beliefs, findings or experiences of someone other than the advertiser. That holds even where those views are identical to the advertiser's own. A board presented on a company's website is that.

Where an advertisement represents that an endorser is an expert, the endorser's qualifications must in fact give them the expertise they are represented as having.

And a claim of expertise is not enough on its own. The endorsement must be supported by an actual exercise of that expertise. The rule specifies an examination or testing at least as extensive as someone with that degree of expertise would normally need to support the conclusions presented.

A name and a credential on a page is not, by that standard, an expert endorsement. It is the represented expertise, without the exercise of it.

The rule written for groups, not individuals

There is a separate provision for endorsements by organizations, and it is the one closest to what a board actually is.

It starts from why a group carries weight at all. An organization's endorsement is viewed as the judgment of a group whose collective experience exceeds that of any individual member, and whose judgments are generally free of the subjective factors that vary between individuals.

Because of that, an organization's endorsement must be reached by a process sufficient to ensure it fairly reflects the collective judgment of the organization. Where the organization is represented as expert, it must use experts it recognizes as such, or standards it previously adopted and that suit judging the products in question.

Two words in there do most of the work. Process, and previously. A conclusion reached after the product existed, by people the company assembled for the purpose, with no adopted standard behind it, is not what that rule describes.

The guides also carry an example about a manufacturer running what appears to be an independent review institute. Because the site falsely appears independent, the example says, it is deceptive.

What has to be disclosed

Where a connection between an endorser and a seller might materially affect the weight or credibility of the endorsement, and the audience would not reasonably expect it, that connection must be disclosed clearly and conspicuously.

The rule spells out what counts. Business, family or personal relationships. Payment. Free or discounted products, including products unrelated to the endorsed one. Other benefits such as early access or the possibility of being paid.

A disclosure does not need every detail of the arrangement, but it must communicate the nature of the connection well enough for a reader to weigh what it means.

So the question about a board is not only who is on it. It is whether the page tells you what the relationship is, in a place you would actually see it.

What an endorsement cannot substitute for

The federal health advertising guidance states the point that matters most in this market.

Advertisers should not make claims through testimonials or expert endorsements that would be deceptive, or could not be substantiated, if the advertiser made them directly.

That closes the loophole a board is sometimes used to open. A clinician's name attached to a claim does not lower the evidence the claim needs. The claim needs whatever it needed before.

Applied here, that is decisive. Most compounds sold in this category are not FDA-approved drugs and the published evidence for them varies enormously by compound. A board cannot change either fact, and an endorsement resting on them inherits them.

What is checkable from outside

Almost every point above turns into something a page either contains or does not.

Are individuals named, with a credential and a state? Without a name nothing else is checkable, by you or by anyone.

Where a name exists, a public federal directory lists health care providers by name, specialty and practice address. It carries its own caution, in its own words: issuance of an identifier does not ensure or validate that the provider is licensed or credentialed. Licensure is confirmed with the relevant state board.

Does the page say what the board actually did, and when? Reviewing a protocol, setting a standard, and appearing in a photograph are three different things.

Is compensation disclosed, and where? Is the board described as independent while being convened and paid by the company, which is the arrangement the organizational rule warns about?

And separately: is the prescriber who will decide your request identified at all, and licensed in your state? That question is unrelated to the board, and it is the one that affects you.

How this site treats them

A published board is recorded as a disclosure, not as evidence. It does not move a score, a grade or a ranking position.

The reason is the one above. The advertising rules describe what an expert or organizational endorsement must be backed by, and nothing visible from outside establishes whether a given board met that standard.

No clinician writes here, and no page here is medically reviewed. Editorial work is signed by a standards editor, a role that owns the ranking rubric, the evidence grades and the price verification dates, and claims no clinical judgment.

Treating someone else's board as evidence while declining to claim clinical review here would be an inconsistency, and it would give a marketing artifact a weight the published rules do not give it.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Title 16 Code of Federal Regulations Part 255, Guides Concerning Use of Endorsements and Testimonials in Advertising, sections 255.0, 255.3, 255.4 and 255.5 — Federal Trade Commission, via the Electronic Code of Federal Regulations, July 2023
2. Health Products Compliance Guidance — Federal Trade Commission, December 2022
3. NPPES NPI Registry public search. It states that issuance of an NPI does not ensure or validate that a provider is licensed or credentialed. The only date printed on the page is the effective date of its query-limit notice — U.S. Centers for Medicare & Medicaid Services, June 2024
4. Getting started with licensure — Telehealth.HHS.gov, Health Resources and Services Administration, February 2024